Aspire Biopharma Holdings Inc (ASBP)

Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)June 12, 2026 10:20 AM
IH Market News Aspire Biopharma has agreed to acquire Dura Driver Control Systems, a global automotive supplier with more than $200 million in annual revenue, significantly reshaping the company’s revenue base and business mix. Key Investor Takeaways Aspire Biopharma (NASDAQ:ASBP) has signed a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash. The acquisition adds a business that generated more than $200 million in revenue and over $22 million in Adjusted EBITDA during 2025. The transaction dramatically diversifies Aspire beyond its pharmaceutical and drug-delivery technology operations. Dura brings a large intellectual property portfolio, including more than 310 patents and relationships with major automotive OEMs. Management stated it does not anticipate raising new equity financing to complete the acquisition. Why ASBP Stock Is in Focus The key development is Aspire Biopharma’s agreement to acquire 100% of Dura Driver Control Systems (DCS), a global manufacturer of automotive driver control technologies. Under the terms of the agreement, Aspire will purchase DCS for $30 million in cash, with the acquired business becoming a wholly owned subsidiary. The transaction is expected to close during the third quarter of 2026, subject to customary closing conditions. DCS operates 11 manufacturing facilities across North America, Europe, and Asia and serves more than 50 customers globally. The company supplies products used in vehicle electrification, safety systems, human-machine interfaces, mechatronic actuators, industrial cables, and control systems. For fiscal 2025, DCS reported more than $200 million in revenue, more than $17 million in net income, and over $22 million in Adjusted EBITDA, according to unaudited figures provided by Aspire. The business also brings a substantial intellectual property portfolio, including more than 310 patents and over 275 proprietary parts supporting more than 150 vehicle platforms worldwide. Why This Matters for Investors This acquisition represents a transformational shift for Aspire Biopharma. Prior to the transaction, Aspire’s investment narrative centered largely on its patent-pending sublingual drug delivery technology and commercialization efforts around its pharmaceutical and nutraceutical products. The addition of DCS introduces a sizable operating business with established revenue, profitability, manufacturing infrastructure, and customer relationships. For investors, the deal may significantly alter Aspire’s financial profile by adding immediate revenue generation, cash flow, and earnings from an operating company that is already commercially established. The transaction also reduces Aspire’s reliance on the longer timelines and development risks often associated with emerging healthcare and biotechnology businesses. Management indicated that the stronger financial foundation could support continued development of its proprietary drug delivery technology while creating additional capital allocation flexibility. At the same time, investors will likely evaluate how effectively management integrates a large automotive supplier into a company whose legacy operations are rooted in biotechnology. The acquisition introduces diversification, but it also creates a business model that spans two very different industries. What to Watch Next Investors will be watching several key developments: Completion of the acquisition during the third quarter of 2026. Details regarding the financing structure used to fund the $30 million purchase. Integration plans for DCS and its global manufacturing operations. Future guidance reflecting the combined company’s revenue and earnings profile. Whether Aspire provides updated capital allocation priorities following the transaction. Continued progress on Aspire’s proprietary drug delivery platform and caffeine product commercialization efforts. The acquisition marks a major strategic pivot for Aspire, transforming it from a primarily biotechnology-focused company into a more diversified enterprise with substantial exposure to the global automotive supply chain. Aspire Biopharma Holdings stock price Original: Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 RevenueJune 12, 2026 8:30 AM
ACCESS NewswireAdds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systemsAcquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profileStrategically diversifies Aspire's revenue streamsOpportunity to drive significant shareholder value creation and enhance long-term capital allocation optionalityCompany does not anticipate procuring new equity financing to consummate the transaction ESTERO, FL / ACCESS Newswire / June 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced the signing of a definitive Share Purchase Agreement ("SPA") for the acquisition of 100% of Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems with expanding industrial applications.The proposed acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise.Key Transaction & Operational Pillars ?Robust Financial Profile: DCS delivered more than $22M in Adjusted EBITDA on over $200M in revenue for FY2025 (unaudited). ?Extensive Intellectual Property: DCS maintains a proprietary portfolio of over 275 distinct parts and more than 310 patents, serving more than 150 vehicle platforms across major global automotive original equipment manufacturers (OEMs). ?Strengthened Management: The existing DCS leadership team will be bolstered by automotive operating and investment professionals from Lakewood & Company, bringing more than 200 years of collective automotive industry, OEM, tier-one supplier, and industrial sector expertise."We are thrilled to welcome the DCS team into Aspire and to build a shared future that creates significant value for all our stakeholders," said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board. "Our acquisition of DCS, an established global automotive systems manufacturer, provides Aspire with immediate, high-volume revenue-generating operations and growth capabilities. Concurrently, this strengthened financial foundation allows us to optimize our proprietary drug delivery technology and advance commercial opportunities for our innovative caffeine product portfolio."Transaction DetailsPursuant to the terms of the SPA, Aspire will acquire 100% of the issued and outstanding shares of DCS, and DCS will become a wholly owned subsidiary of the Company. Aspire is purchasing these shares for $30.0 million in cash. DCS CEO Hans Vorstenbosch will continue as CEO of the DCS subsidiary with the existing DCS management team under the leadership of Gregory J. Corona, the Chairman of Lakewood & Company.DCS Financial SummaryDCS is a tier-one supplier specializing in high-growth vehicle electrification, safety, and human-machine interface (HMI) systems. For the fiscal year ended December 31, 2025 (unaudited), DCS generated revenue of more than $200 million, net income of more than $17 million and Adjusted EBITDA of more than $22 million. Adjusted EBITDA is a non-GAAP financial measure.Non-GAAP Financial Measure Notice: DCS defines Adjusted EBITDA as earnings before interest expense, income tax, depreciation, and amortization, inclusive of specifically identified adjustments. The Company believes Adjusted EBITDA provides useful supplemental information to investors regarding DCS's operational and financial performance. Adjusted EBITDA as presented herein may not be comparable to similarly titled measures reported by other companies.DCS Highlights ?Global Manufacturing Scale: Operates 11 global facilities strategically located across North America, Europe, and Asia. ?Deep IP & Engineering Footprint: Supported by 310+ patents and 55 dedicated design and product engineers across two global technical centers located in close proximity to major customer hubs. ?Blue-Chip Customer Base: A diversified portfolio of more than 50 customers, highlighted by an average relationship longevity of 28 years with its top 10 OEM clients, supporting more than 150 vehicle platforms and 250 high-volume, global vehicle models. ?Fundamental Operations: Years of solid revenue and consistent free cash flow generation.Timing and ApprovalsThe transaction is expected to close in the third quarter of 2026, subject to the satisfaction of customary closing conditions set forth in the definitive Share Purchase Agreement.AdvisorRBW Capital Partners LLC is acting as exclusive financial advisor to the Company in connection with the acquisition. Any securities or brokerage services will be offered through Dawson James Securities, Inc.About Dura Driver Control SystemsDCS is a leading designer and manufacturer of highly engineered automotive and industrial systems that facilitate electronic driver control and support the migration toward vehicle electrification, safety, lightweighting, and sustainability. DCS maintains a strong powertrain agnostic product portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms.About Aspire Biopharma Holdings, Inc.Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific to the proposed acquisition of DCS include, without limitation: the risk that the proposed transaction may not close on the terms or timeline currently contemplated, or at all; the risk that due diligence, including the audit of DCS's financial statements under U.S. GAAP, may reveal information that adversely affects the terms or viability of the transaction; risks related to DCS's business, including its dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential liabilities associated with DCS's operations and intellectual property, the ability to successfully integrate DCS's operations following closing, and the risk that anticipated financial benefits from the acquisition may not be realized, including the risk that the business operations and strategies of DCS and Aspire may diverge. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Why is the price going down on news?

Anyone know anything about a share buy back?

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of MembersMay 27, 2026 8:30 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members. The EoS Flex Deals affiliate program is a premier partnerships platform designed to connect members with brands aligned with the EoS mission. With over 80 million impressions in 2025, the program provides BUZZ BOMB™ with a powerful ecosystem to drive engagement, brand visibility and revenue, via in-gym TV advertising, Flex Deal mobile app offers and on-site product demonstrations.Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.Buzz Bomb Caffeine Company will be rolling out a variety of marketing initiatives andcollaborative content that maximizes awareness, including in-club digital assets, webfeatures, member communication and more."Partnering with EoS Fitness to bring our caffeine product to millions of members is a pivotal step for BUZZ BOMB™," said Kraig Higginson, CEO of Aspire. "We're meeting our customers where they are - in a premium environment that reflects their commitment to an intentional, high-performance lifestyle. By integrating our high-efficacy products into the EoS Fitness experience, we are empowering members to achieve peak performance, inside and out."BUZZ BOMBTM Caffeine ProductsBUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.To learn more about BUZZ BOMB™, or purchase products online, please visithttps://buzzbombcaffeine.com or follows us on social media here:FacebookInstagramTikTokAbout Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.Contact:PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may,""might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress ofclinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

ASBP............................p/m

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split RatioMay 7, 2026 11:00 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".The reverse split is primarily intended to bring Aspire into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq. The new CUSIP number for the Common Stock following the reverse split will be 738920305.At Aspire's special meeting of stockholders on April 10, 2026 (the "Special Meeting"), Aspire's stockholders approved the proposal to authorize Aspire's board of directors (the "Board"), in its sole and absolute discretion, to file a certificate of amendment (the "Amendment") to Aspire's amended and restated certificate of incorporation to effect the reverse split of the Company at a ratio of one-to-thirty (1:30). On April 24, 2026, the Board approved the reverse split at a ratio of one-to-thirty (1:30), and the Amendment has been filed with the Secretary of State of the State of Delaware, which will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on the Nasdaq.The reverse split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock awards, warrants and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under any Equity Incentive Plan, will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 per share. The reverse split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares of Common Stock shall be issued as a result of the Reverse Split, and stockholders who otherwise would be entitled to receive fractional shares of New Common Stock shall be entitled to receive the number of shares of New Common Stock rounded up to the next whole number. The reverse split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in Aspire's equity (other than as a result of the rounding of fractional shares, as set forth above).The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 36,329,490 million to approximately 1,210,983 million.About Aspire Biopharma, Inc.Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementCertain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

BULLISH!!!
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

ASBP...............................https://stockcharts.com/sc3/ui/?s=ASBP&p=w&b=5&g=0&id=p86431144783

ASBP wake up already. 🤦

This seems to be consolidating in the .20-.22 range. This should have a breakout at some point.

https://profiles.smallcapsdaily.com/asbp/

Lots of pre market volume. Maybe this gets back to the 20SMA today.

Buys catching up.

why so much volume? Only 5.02 shares outstanding! What's up?

ASBP trying to make a comeback here a green close would be nice.

Man another red day. I'm at a lost for words right now.

I think if this gets past .33 today this might run. I'm hoping

130M volume! Seems like a slightly delayed response to the NEWS from yesterday...



Link 👉️ 8K Press Release

$ASBP

Yes i see. My dumb dog woke me up and i decided to check on ASBP early this morning. Why all this volume Pre Market?

+72% @ .45 on 45M volume! 🚀

20M volume 1st 20 minutes premarket wOw $ASBP

+50% @ .39! 8.5M volume premarket! Early premarket! 😺

.37! Volume 4.4 million! Hang ON!

1,320,339 volume in the first 7 minutes...😺 $ASBP

+23% @ .32, Law of Averages, here we go...😺

$ASBP

I thought we would be much higher than this. Stock seems to be struggling on a good PR today. Hopefully this will close in the green today

Got some movement here. I'm looking for resistance to get broken at .57

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS AcquisitionApril 20, 2026 8:30 AM
ACCESS NewswireCompany secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock.Pursuant to the closing of the second and final tranche of the Offering, the Company issued an aggregate of 12,500 Preferred Shares for gross proceeds of $10.0 million. With the completion of this tranche of the Offering, total aggregate gross proceeds to the Company were $21.0 million, before deducting placement agent fees and other offering expenses. Based on the total proceeds, the Company's stockholders' equity now exceeds the $2.5 million minimum required to maintain its listing on the Nasdaq Capital Market.The Company intends to use the net proceeds from the transaction to support working capital, to fund a portion of the cash component of the proposed DCS acquisition, and other general corporate purposes.Additional information regarding the Offering is available in the Company's Current Report on Form 8-K/A filed on April 17, 2026 with the SEC."Finalizing this $21 million raise is a transformative step for Aspire," said Kraig Higginson, Interim CEO. "These funds solidify our capital position as we advance our sublingual delivery platform and accelerate consumer awareness and retail expansion of BUZZ BOMB™, our innovative caffeine product. Simultaneously, we are executing a dual-track growth strategy, by pursuing a high-revenue, cash-flow-positive acquisition of DCS that, if consummated, could substantially enhance our financial position."LOI to Acquire DCSThe Company announced on April 15, 2026 that it has entered into a Letter of Intent (LOI) to acquire DCS, a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. DCS delivered more than $20M in Adjusted EBITDA on $200M+ Revenue for FY2025 (unaudited). Aspire is expected to acquire 100% of DCS for a total purchase price of $30million paid in cash.Commenting on the Company's recently announced intent to acquire DCS, Higginson said, "The potential acquisition of this established automotive systems manufacturer could introduce significant revenue-generating capabilities while allowing us to optimize our drug delivery technology and advance commercial opportunities. Our intent is to acquire DCS without any additional equity capital by utilizing a new senior secured credit facility, once finalized, with a leading financial institution. We believe the combination of significant revenue from the automotive systems business and the potential high margin opportunities from both our drug and supplement product pipeline could strengthen earnings visibility, support a more capital-efficient growth model, and enhance long-term shareholder value."Aspire Enters into Commitment Letter for Acquisition of DCSThe Company entered into a commitment letter with a national financial institution providing for a senior secured credit facility of Aspire in an aggregate principal amount of up $22,500,000 (the "Aspire Credit Facility"). Aspire intends to use the proceeds of the Aspire Credit Facility, if consummated, to finance the acquisition of 100% of DCS. The Company does not anticipate procuring any new equity raise to consummate the purchase.The Aspire Credit Facility is expected to consist of a senior secured five-year term loan, at an interest rate equal to 325 basis points above the one-month term Secured Overnight Financing Rate. The final terms of the Aspire Credit Facility, including the senior secured term loan, will be subject to execution of definitive credit documentation and the satisfaction of customary closing conditions.Offering AgentRBW Capital Partners LLC, whose securities and brokerage services are offered through Dawson James Securities, Inc., acted as sole placement agent for the private placement.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Aspire Biopharma Holdings, Inc.Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific to the proposed acquisition of DCS include, without limitation: the risk that the parties may fail to finalize a definitive acquisition agreement or that the proposed transaction may not be consummated on the terms or timeline currently contemplated, or at all; the risk that due diligence, including the audit of DCS's financial statements under U.S. GAAP, may reveal information that adversely affects the terms or viability of the transaction; risks related to DCS's business, including its dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential liabilities associated with DCS's operations and intellectual property, the ability to successfully integrate DCS's operations following closing, consummation of the Aspire Credit Facility, and the risk that anticipated synergies and financial benefits from the acquisition may not be realized. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

I'm hoping the bottom was in at .2522

Good luck to you as well.

3 and a half bagger 🤑 I'm all in GLTY $ASBP

I'm thinking this has to get back to the 20SMA .97

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon ExpoApril 17, 2026 8:00 AM
ACCESS NewswireElite Ultra-Marathoner targets her second World Record in two months following historicUltra Jackpot 100 WinESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, is proud to announce that elite ultra-marathoner and BUZZ BOMB™ Global Brand Ambassador Ashley Paulson will attempt to shatter the female world record for the fastest 100-mile treadmill run.The historic attempt will take place live at the Boston Marathon Expo at the John B. Hynes Veterans Memorial Convention Center on Saturday, April 18, 2026. This Expo is held in conjunction with the Boston Marathon. Paulson aims to beat the current mark of 14:15:08, pushing the limits of human endurance in front of thousands of spectators during one of the most prestigious weekends in global running."Ashley embodies the grit and rapid performance that BUZZ BOMB™ was designed to support," said Kraig Higginson, Interim CEO of Aspire Biopharma. "After her dominant road world record in February, we are thrilled to fuel her next history-making effort in Boston."Paulson is no stranger to the record books. On February 20, 2026, she set the current world record for the fastest female to run 100 miles (road) at the Jackpot 100 Mile Ultra with a staggering time of 12:19:34. This upcoming challenge transitions her elite speed to the treadmill, a feat requiring immense mental and physical fortitude.Commenting on her use of BUZZ BOMB™ throughout the 100 Mile Ultra race, Ashley Paulson said, "I was using a BUZZ BOMB™ every hour to keep my energy steady while chasing the 100-mile world record. The easy delivery under the tongue kicks in fast without the upset stomach issues of traditional caffeine. It's just smooth, consistent energy that kept me cruising mile after mile."Paulson's upcoming attempt will showcase her endurance and the mental fortitude required for long-distance treadmill running. This event highlights the intersection of elite athleticism and specialized performance support during one of the most significant weekends in the running community. Please come and meet Buzz Bomb representatives that will be supporting Ashley at the Expo!Event Details:Athlete: Ashley PaulsonGoal: Fastest Female 100-Mile Treadmill Run (Target: < 14:15:08)Date: Saturday, April 18, 2026Location: Boston Marathon Expo, Hynes Convention Center, 900 Boylston St, Boston, MAAshley Paulson Wins the 2026 USATF 100-Mile Road ChampionshipFor more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.https://www.instagram.com/ashkickn/?hl=en,https://www.tiktok.com/@ashkickn1https://www.facebook.com/ashley.j.paulson/BUZZ BOMB™ Caffeine ProductsUnlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:FacebookInstagramTikTokBUZZ BOMB™ Variety PackAbout Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

In @ .30... 😺 ...Floor Price of $0.264 per share.



https://lakewoodcompany.com/criteria/

From today's Press Release: DCS is a tier-one supplier specializing in vehicle electrification, safety, and human-machine interface (HMI) systems. For the fiscal year ended December 31, 2025 (unaudited), DCS generated revenue of more than $200 million, net income of more than $17 million and Adjusted EBITDA of more than $22 million.Link to PR 👉️ ASBP Press Release April 16, 2026

$ASBP



OS = 5M plus 160M shares more for the acquisition...? 165M OS
Revenues are > $200M and profitable ~$17M Net Income deserves a Market Cap of 2x Sales/Revs = $400M.
$400M / 165M OS = 2.42 per share. ~17M Net Income / 165M OS = 0.103 per share. PE Ratio of 20 = 2.06 per share.

They have to cut ASBP's losses though...CURRENT PRICE $0.2907.

ASPIRE BIOPHARMA HOLDINGS, INC.
RESALE OF UP TO 159,090,906 SHARES OF COMMON STOCK UNDERLYING SERIES A CONVERTIBLE PREFERRED STOCK

This prospectus relates to the offer and sale from time to time by the selling shareholders named in this prospectus (the “Selling Shareholders”) of up to an aggregate of up to 159,090,906 shares (the “Conversion Shares”) of Aspire Biopharma Holdings, Inc. (the “Company”) Common Stock, par value $0.0001 per share (“Common Stock”) issuable upon the conversion of certain Series A Convertible Preferred Stock (the “ Preferred Stock”). The Preferred Stock were issued in connection with a Securities Purchase Agreement dated February 6, 2026 (the “Purchase Agreement”) between the Company and the Selling Shareholders for up to an aggregate purchase price of $20,000,000. The initial closing of the issuance of Preferred Stock occurred at the closing under the Purchase Agreement on February 6, 2026, at which point the Company issued 13,750 Shares of Preferred Stock for aggregate gross proceeds of $11,000,000 million (the “First Tranche”), including $943,801 of debt that converted into Preferred Shares on the same terms. Subject to the satisfaction or waiver of certain conditions set forth in the Purchase Agreement, a second closing may take place, pursuant to which the Company may issue up to 12,500 additional Shares of Preferred Stock for aggregate proceeds not to exceed $10,000,000 (the “Second Tranche”), which will be contingent on the effectiveness of this registration statement. The Preferred Stock are convertible into the Conversion Shares subject to certain conditions more fully described in the Purchase Agreement.

The Preferred Stock is convertible (in whole or in part) immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% of the shares of Common Stock that would be issued and outstanding following such conversion. The conversion price means the greater of (i) eighty (80%) percent of the lowest Closing Price on any Trading Day during the five (5) Trading Days prior to the applicable conversion date or (ii) the floor price (the “Floor Price”). The Floor Price means 20% of the average closing price of our Common Stock for the five days prior to the Closing Date which equates to a Floor Price of $0.264 per share.

Link 👉️ SEC FORM S-1/A

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail ExpansionMarch 19, 2026 8:00 AM
ACCESS NewswireAgreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser ChannelsESTERO, FL / ACCESS Newswire / March 19, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, and TruLife Distribution ("TruLife"), announced they have concluded an agreement under which TruLife will manage and coordinate the sales, distribution and merchandising of BUZZ BOMB™ to retailers nationwide.TruLife Distribution is a premier agency known for scaling high-growth health and wellness brands. This relationship is designed to accelerate BUZZ BOMB's retail footprint, specifically targeting the natural, organic, specialty, and mass-market sectors where demand for functional, "on-the-go" energy is surging.The BUZZ BOMB™ Advantage: Energy Without the Liquid
BUZZ BOMB™ is disrupting the traditional energy market with its innovative caffeine delivery. Each single-serving stick pack contains 50mg of caffeine in a fast-acting dry powder designed to be sprinkled under the tongue. This allows for a rapid caffeine boost without the need for water, mixing, or the "heavy" feeling of liquid energy drinks."We are pleased to engage in new distribution relationships that will continue to drive our sales and enhance our ability to reach consumers interested in our unique BUZZ BOMB™ caffeine product," said Kraig Higginson, Interim CEO of Aspire Biopharma. "The energy segment offers exceptional growth and can be a highly profitable category. TruLife's expertise in reaching retailers opens a significant new and incremental sales channel for BUZZ BOMB™ that is expected to support our efforts to bring the BUZZ BOMB™ brand to even more contemporary consumers, strengthening our business.""In a category full of products pushing the safe upper limit for daily caffeine intake, BUZZ BOMB™ offers a convenient, small-serving alternative with impressive benefits. We are truly excited to represent the BUZZ BOMB™ brand and bring clean energy to a wider audience," said Brian Gould, TruLife CEO and decades-long veteran of the health and wellness industry.BUZZ BOMB™ Caffeine ProductsTo learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:Facebook
Instagram
TikTokAbout TruLife DistributionTruLife Distribution is a leading full-service distribution and marketing firm that helps health, wellness, and beauty brands navigate the complexities of the U.S. retail market.Learn more about TruLife Distribution at trulifedist.com.About Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales DirectorMarch 17, 2026 8:30 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.Choe joins Buzz Bomb following a successful tenure as District Manager at Yerbaé (2016-2025), where he specialized in the natural energy drink category, achieving a 70% increase in overall sales within a highly competitive market. He accomplished this by spearheading the development of brand ambassador programs and innovative marketing tools tailored to both identified and untapped consumer segments. His strategic use of S.W.O.T. analysis and his ability to navigate complex DSD (Direct Store Delivery) and wholesale relationships with partners like WinCo, KeHE, and Kroger was instrumental to his success."John's deep expertise in the beverage and retail sectors, combined with a visionary approach to market analysis and consumer engagement, makes him an ideal leader to spearhead our sales strategy in the western United States," stated Kraig Higginson, Interim CEO of Aspire Biopharma. "The ability to build productive relationships and a creative approach to reaching both identified and untapped consumer segments will be instrumental as the brand continues to scale."Choe's extensive background includes pivotal roles at global brands such as:Nike (1999-2005): Managed major accounts like Nordstrom and specialized in futures ordering across Northern and Southern California.Mars Candy (2005-2009): Led sales and merchandising efforts for massive retail outlets including Walmart, Target, and Safeway.Bosch (2009-2012): Spearheaded training and product education for retail giants Home Depot, Lowe's, and Ace Hardware.With 11 years of dedicated supervisory experience, Choe is a specialist in hiring, mentoring, and coaching direct reports to peak performance. His leadership style emphasizes compliance, accountability, and the development of talent. Furthermore, his fluency in Korean, Chinese, and Japanese provides a unique edge in engaging with diverse markets."I am thrilled to join BUZZ BOMB™ at such a pivotal moment in its growth trajectory," said John Choe. "The energy category is evolving quickly, and I look forward to leveraging my experience in retail partnerships to expand our footprint and bring Buzz Bomb's innovative products to a wider audience."John Choe holds a Master of Business Administration from the University of Phoenix and a Bachelor of Science in Business Management from the University of Utah.BUZZ BOMB™ Caffeine ProductsTo learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:FacebookInstagramTikTokAbout Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store PackMarch 10, 2026 8:30 AM
ACCESS NewswireConvenient Size at the Convenience StoreESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB™ Convenience Store Pack.Convenience stores are where many of today's quick decisions happen, and the checkout counter plays a big role in those moments. By introducing BUZZ BOMB™ into that space, we are giving the consumer greater choice and making BUZZ BOMB™ easier to enjoy and more accessible. This expansion is part of Buzz Bomb Caffeine Company's broader strategy to evolve with people's needs, energize convenience retail and drive growth across the caffeine category.The LineupThe lineup includes the newly designed six-count "Fruit Blast" package containing two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango, allowing for packaging options that fit changing habits.BUZZ BOMB™ Convenience Store PackThe Caffeine Evolution: No Liquid, No Limits
BUZZ BOMB™ is a fast-acting dry powder delivered in a single-serving stick pack designed to be sprinkled directly under the tongue. Unlike traditional energy drinks or pills, this serving method allows for a rapid caffeine boost without the need for water, mixing, or consuming large volumes of liquid.Key Product Highlights:Precision Dosing: Each stick pack delivers 50mg serving of caffeine.Ultimate Portability: Slim, light, single-serving packs fit easily into pockets, gym bags, or car consoles.Six pack "Fruit Blast" Offering: Featuring two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango.Clean Energy: Ideal for athletes, professionals, and students seeking a quick, affordable alternative to coffee or soda."We are redefining how the world consumes caffeine," said Kraig Higginson, Interim CEO of Aspire Biopharma. "By moving into the convenience store sector, we are meeting our customers exactly where they need us-on the go, providing a precise, flavored caffeine hit that we believe works faster than a beverage."The BUZZ BOMB™ Convenience Store Packs will begin appearing on shelves in select locations starting in May.BUZZ BOMB™ Caffeine ProductsUnlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:Facebook
Instagram
TikTokAbout Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon SponsorshipFebruary 25, 2026 8:30 AM
ACCESS NewswireBUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced a massive expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company. The initiative follows a successful strategic rebranding and a high-profile sponsorship of professional ultra-marathoner Ashley Paulson, whose recent world-record performance catalyzed a significant increase in brand visibility and consumer acquisition.BUZZ BOMB™-a caffeine supplement delivering a precise 50mg serving in convenient and flavorful stick packs-has seen its social media content surpass 400,000 views in a 48-hour period after the race. This digital momentum coincides with the brand's recent evolution, featuring a sleek modern website and science-forward packaging designed to appeal to high-performance athletes and everyday consumers alike.The brand's visibility reached a fever pitch at the 2026 Jackpot Ultra Running Festival. BUZZ BOMB™ Brand Ambassador Ashley Paulson set a new women's world record during the USATF 100-Mile Road Championship, winning the event by over two hours with a staggering time of 12:19:34 (breaking the old record by more than 20 minutes). Competing in her signature pink ponytail and BUZZ BOMB™ gear, Paulson credited her use of BUZZ BOMB™ caffeine supplements for helping her maintain her 7:21 per mile pace throughout the 100-mile race. Ashley's accomplishments were highlighted in Runner's World and on the US Track and Field web sites. Runner's World featured an article about Ashley's record."We are thrilled that our brand ambassador, Ashley Paulson, achieved a first-place finish for women at the Jackpot Ultra Running Festival," said Kraig Higginson, Interim CEO of Aspire Biopharma. "We didn't just want a face for the brand; we wanted an elite athlete who relies on our caffeine products to perform at the highest level possible. Ashley's world record-breaking win supports our belief that BUZZ BOMB™ is the ultimate tool for sustained performance."Buzz Bomb Caffeine Company team members were there to cheer Ashley and in a post-race interview with her sponsor, she said, "Honestly, it doesn't feel real. I'm like, has this really happened? ... I worked so hard for it, but it came, it happened. Dreams come true, you just got to keep fighting for it and show up, put in the work, and then execute."Ashley Paulson Wins the 2026 USATF 100-Mile Road Championship For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.https://www.instagram.com/ashkickn/?hl=en,https://www.tiktok.com/@ashkickn1https://www.facebook.com/ashley.j.paulson/BUZZ BOMB™ Caffeine ProductsUnlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:FacebookInstagramTikTokBUZZ BOMB™ Variety Pack About Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma Regains Full Compliance with Nasdaq Listing RequirementsFebruary 20, 2026 8:00 AM
ACCESS NewswireCompany achieves minimum stockholders' equity rule; Nasdaq confirms matter is closedAspire maintains listing on the NasdaqESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it had received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.The Company is now in full compliance with all Nasdaq continued listing requirements and the Company's common stock will remain listed and traded on the Nasdaq Stock Market.Notwithstanding the compliance determination, the Company was also notified that it will remain subject to a "Panel Monitor," as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through February 18, 2027. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the $2.5 million equity requirement, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company's listing on Nasdaq pending completion of the hearing process.About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of RecordFebruary 19, 2026 8:00 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record.The appointment comes as BUZZ BOMB™ gears up for a transformative year focused on aggressive brand expansion, product innovation, and a refreshed market presence. ChicExecs, a powerhouse agency with offices in six states and a portfolio of over 250 global brands, will spearhead BUZZ BOMB™'s communications strategy. The focus includes media relations, high-impact events, strategic partnerships, and PR-led campaign planning."The ChicExecs team is thrilled to partner with Buzz Bomb Caffeine as they reshape the energy category, delivering sharp focus, instant energy, and no crash," said Kristen Wessel, Senior Vice President of Public Relations at ChicExecs. "Their innovative approach to clean, convenient energy solutions aligns seamlessly with our mission to elevate trailblazing brands. We're excited to amplify their journey, grow their audience, and drive meaningful growth in the marketplace through this exciting new partnership.""As BUZZ BOMB™ enters this next stage of growth, we are thrilled to partner with ChicExecs to bring our brand story to life in new and meaningful ways," said Kraig Higginson, Interim CEO of Aspire. "Together, we are redefining how we connect with consumers, highlighting our innovative formulation, and reinforcing our leadership in the rapid caffeine delivery space. ChicExecs' decades of experience in elevating mission-driven brands makes them the ideal collaborator to amplify our reach."The partnership marks a pivotal chapter for BUZZ BOMB™ as it leverages a comprehensive brand refresh. ChicExecs will utilize its deep sector expertise in food and beverage, fitness, and lifestyle products to position BUZZ BOMB™ as the premier innovator for athletes, professionals, and anyone requiring a rapid, efficient energy boost. Beyond consumer awareness, the agency will also drive thought-leadership campaigns to support Aspire's broader corporate recruitment and industry positioning.BUZZ BOMB™ Caffeine and Sublingual DeliveryUnlike traditional energy drinks or pills, BUZZ BOMB™ utilizes a proprietary format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single-serving stick packs.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.BUZZ BOMB™ Variety Pack About Aspire Biopharma Holdings, Inc.Aspire Biopharma delivers supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.com.Aspire Biopharma Holdings, Inc.Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma Announces the Appointment of New Member to Its Board of DirectorsFebruary 13, 2026 8:00 AM
ACCESS NewswireNew independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platformESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6, 2026. The appointment follows the planned departures of Suren Ajjarapu and Donald G. Fell, from the board."On behalf of our Board, I am delighted to welcome Phillip to the Aspire Biopharma Board. His leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen," said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board. "We are confident that his insights will help accelerate our strategy of reformulating established drugs with large markets and reinforce the Company's commitment to patients, customers, and shareholders."Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son.In addition to his capital markets career, Mr. Balatsos brings entrepreneurial and operating experience, having founded and scaled a multi-location hospitality business and advised national restaurant groups on procurement, pricing, and operational efficiency. This background provides a pragmatic operator's perspective on margins, cost structures, and execution-particularly valuable in growth and turnaround environments.Mr. Balatsos currently serves on the Boards of Directors of Inspire Veterinary Partners, Inc., where he is a member of the Audit Committee, and Ciso Global, Inc., a cybersecurity and risk management company. He previously served on the Board of Sadot Group Inc., contributing to its transformation from a restaurant operator into a global agri-commodity trading and food supply chain business, and serving on both the Audit and Executive Compensation Committees.He holds a Bachelor of Science in Business Administration from Skidmore College, with a minor in International Relations and a concentration in Spanish.Phillip Balatsos will serve on the Audit and Compensation Committees."The Company's mission to provide rapid-onset therapeutics through novel sublingual formulations resonates strongly with my experience in scaling growth-stage companies," said Mr. Balatsos. "I look forward to supporting this team as they advance their platform and drive the next phase of growth and innovation."About Aspire Biopharma Holdings, Inc.Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq RequirementsFebruary 11, 2026 7:45 AM
ACCESS NewswireESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has entered into a securities purchase agreement on February 6, 2026 (the "Securities Purchase Agreement") with select institutional and accredited investors (collectively, the "Investors") for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock (each, a "Preferred Share" and collectively, the "Preferred Shares"), at a purchase price of $800 per Preferred Share. The Preferred Shares are convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), representing aggregate gross proceeds to the Company of up to $21.0 million, before deducting placement agent fees and other offering expenses (the "Offering").Concurrently with the execution of the Securities Purchase Agreement, the Company completed the initial closing (the "Initial Closing") of the Offering on February 6, 2026, issuing an aggregate of 13,750 Preferred Shares for gross proceeds of $11.0 million, before deducting placement agent fees and other offering expenses and amounts used for the repayment of certain legacy indebtedness. In accordance with the Securities Purchase Agreement, a portion of the proceeds from the initial closing will be used to support the Company's legacy business operations, fund strategic initiatives and pay offering-related expenses. The second closing of the Offering is expected to occur at a later date and remains subject to the satisfaction of customary closing conditions and the other conditions set forth in the Securities Purchase Agreement, which has been filed with the Securities and Exchange Commission (the "SEC'). Additional information regarding the Offering is available in the Company's Current Report on Form 8-K filed on February 11, 2026 with the SEC.The Offering is expected to enable the Company to regain compliance with Nasdaq's stockholders' equity listing requirements, representing an important milestone in the Company's ongoing balance sheet restructuring and positioning the Company to support the continued development of its patent-pending drug delivery technologies.Following the Initial Closing, the Company expects to significantly reduce its outstanding indebtedness and further strengthen its balance sheet, enhancing financial flexibility and providing additional resources to advance its clinical and development initiatives while supporting long-term shareholder value.RBW Capital Partners LLC, whose securities and brokerage services are offered through Dawson James Securities, Inc., acted as sole placement agent for the private placement.The securities being offered and sold by the Company in the Offering have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares issuable upon the conversion of the Preferred Shares.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Aspire Biopharma Holdings, Inc.Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition SummitFebruary 5, 2026 8:00 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a proprietary sublingual caffeine supplement today announced its participation at The Sports & Active Nutrition Summit USA, scheduled for February 18-20 in San Diego, CA. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the event.The Sports & Active Nutrition Summit USA is a premier industry gathering that unites leaders in sports nutrition and active lifestyle innovation. The summit explores the intersection of scientific research, ingredient development, business strategy, and consumer trends through expert-led presentations, startup showcases, wellness programs, and extensive networking opportunities, helping attendees stay ahead in the evolving market of performance-oriented nutrition. The summit presents opportunities for networking and marketing to retailers of innovative products like BUZZ BOMB™The participation of Buzz Bomb Caffeine Company at the Summit follows the recent launch of the redesigned BUZZ BOMB™ website, https://buzzbombcaffeine.com, which offers a seamless, mobile-optimized, and user-friendly experience. This digital enhancement is complemented by refreshed product branding, including a new logo and modern packaging designed to better reflect the product's innovative capabilities.BUZZ BOMB™ Caffeine and Sublingual Delivery
Unlike traditional energy drinks or pills, BUZZ BOMB™ utilizes a proprietary sublingual format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method delivers pure caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs."The Sports & Active Nutrition Summit provides an excellent platform to demonstrate the rapid onset and convenience of our sublingual caffeine compared to conventional caffeine formats like sodas and energy drinks," said Kraig Higginson, Interim CEO of Aspire. "We look forward to connecting with industry innovators and showcasing how BUZZ BOMB™ is poised to disrupt the active sports and fitness supplement market."JOIN US!Date: February 18-20, 2026
Location: San Diego, CAJoin us in San Diego from February 18-20 for three days of innovative insights, industry networking, and discussions shaping the future of sports and active nutrition.Visit us at the show for BUZZ BOMB™ samples, insightful conversations, and a chance to connect directly with our team.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.BUZZ BOMB™ Variety PackAbout The Sports & Active Nutrition Summit Series
The Sports & Active Nutrition Summit Series brings together industry professionals to bridge the gaps between cutting-edge science, business strategy, and key regulatory developments. It offers a one-stop shop for the latest must-have insights into the worlds of sports and active nutrition. The three-day interactive summit takes place annually in Europe and the US. To learn more, visit the event website at https://sportsnutritionsummit-usa.com/live/en/page/homeAbout Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a sublingual delivery method that can deliver supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California DistributionFebruary 3, 2026 8:00 AM
ACCESS NewswireESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB™, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the Los Angeles and San Diego metropolitan areas.Blue Shark Beverages, a family-owned independent distributor, services retail channels throughout Southern California. By leveraging Blue Shark's established network, BUZZ BOMB™ aims to capture the growing "better-for-you" energy market with its portable, fast-acting caffeine product."We are thrilled to bring BUZZ BOMB™ to the premier resorts, hotels, and casinos of Palm Springs and the Coachella Valley," said Kara Topolsky, Founder and CEO of Blue Shark Beverage. "As the first to introduce this innovative sublingual energy supplement to our local market, we are especially excited for its debut at the upcoming Coachella and Stagecoach Festivals. Festival weekends are a marathon and BUZZ BOMB™ is the ultimate companion for fans who need instant energy to keep the celebration going.""The demand for functional, health-conscious fitness supplements is accelerating as consumers pivot away from traditional sugary energy drinks and stomach-aggravating sodas," said Kraig Higginson, Interim CEO of Aspire. "Blue Shark Beverages has a proven track record of scaling emerging brands through superior service and deep regional expertise. This collaboration is a pivotal first step in our 2026 strategy to increase placement of our BUZZ BOMB™ product where our customers live, work and play, through a diversity of channels and geographic locations."BUZZ BOMB™ Caffeine and Sublingual DeliveryAccording to Grandview Research , the global energy drinks market size was estimated at $79.39 billion in 2024 and is projected to reach $125.11 billion by 2030, growing at a CAGR of 8.0% from 2025 to 2030. Energy drinks have become increasingly popular among fitness enthusiasts and athletes due to their ability to provide a quick energy boost.Unlike traditional energy drinks, coffee, or soda, BUZZ BOMB™ utilizes a proprietary sublingual format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method delivers pure caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise amount of caffeine with the convenience of single-serving stick pack.To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.About Aspire Biopharma Holdings, Inc.Aspire Biopharma has developed a sublingual delivery method that can deliver supplements to the body rapidly and precisely.For more information, please visit www.aspirebiolabs.comAspire Biopharma Holdings, Inc.ContactPCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.comSafe Harbor StatementThis press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.SOURCE: Aspire Biopharma Holdings, Inc.View the original press release on ACCESS NewswireOriginal: Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Adding more shares here. Still a super-sleeper favorite for me.

ASBP...................................https://stockcharts.com/sc3/ui/?s=ASBP&p=w&b=5&g=0&id=p86431144783

ASBP monster

ASBP POST RS BIO BEAST

tanking today .05